Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technique Rapidly Detects Needle-in-a-Haystack Plasma Biomarkers for Disease Diagnosis

By LabMedica International staff writers
Posted on 12 May 2023

Blood plasma, routinely collected during medical care and research, has the potential to be an abundant source of protein biomarkers. More...

These markers can serve diagnostic and prognostic roles, measure treatment response, and provide insights into disease biology. However, finding such biomarkers in plasma using proteomics, the most advanced tool currently available, is challenging. This is because 99% of plasma is composed of common proteins like albumin, globulins, and coagulants that essentially hide potential biomarkers. These same proteins are repeatedly identified in a plasma sample, making the detection of the less abundant but interesting proteins difficult. While scientists have attempted to remove these common proteins from plasma samples using antibodies, the process has been found to be costly, time-consuming, and not robust enough for large-scale usage. Now, a team of researchers has developed a new, rapid, and cost-effective method to remove these proteins by repurposing an old biochemical technique from 1948.

Researchers at Boston Children's Hospital (Boston, MA, USA) came upon a technique previously mentioned in literature on protein and peptide studies that could be applied to plasma. During the COVID-19 pandemic, the researchers were tasked with analyzing the proteins in 5,000 plasma samples for a study looking at immune responses in about 1,100 hospitalized COVID-19 patients. This task had to be accomplished at a time when many labs were closed due to the pandemic. In a span of three months, the researchers had to develop a method to analyze ten times the amount of plasma samples than they typically handled daily. The team successfully accomplished this task, and their work contributed to the identification of tissue- and organ-specific biomarkers, which accurately predicted the progression of hospitalized COVID-19 patients.

This new technique employs perchloric acid, a very potent superacid, along with very low temperatures (-20°C) to separate the common proteins within as little as 15 minutes, without harming the remaining proteins. The unwanted proteins coagulate similar to how milk curdles in lemon juice. The samples can then be centrifuged, and the liquid at the top, which contains the required proteins, can be collected. This method is fast enough for large-scale use, depleting the unwanted proteins at a cost of only USD 2.50 per sample, significantly lower than current costs. This technique enables the detection of over 1,500 proteins per sample at a rate of 60 samples per day.

Related Links:
Boston Children's Hospital 


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.